Addiction Cure – Naltrexone


 

Addiction Cure – Naltrexone – Look it up. Naltrexone breaks the cycle of addiction and brings new hope for alcohol dependence and opiate drug addiction. How long will the FDA keep it available? Why aren’t we hearing about this? Naltrexone is one of the first anti-craving medications approved by the US Food and Drug Administration (FDA) for use in the treatment of alcoholism and opiate addiction. In clinical trials, LDN has been shown to halt disease progression in Crohn’s disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis (MS) and autism. Ongoing trials are evaluating LDN in fibromyalgia and HIV/AIDS. Anecdotally, LDN has been shown to improve almost every autoimmune and neurodegenerative condition, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Naltrexone modulates the immune system and promotes healing. Naltrexone comes in two forms: 1) Vivirol®-an injectable time released form of naltrexone that is taken once a month. Visit Vivitrol’s website for more information. 2) ReVia© or naltrexone- taken daily in pill form. Here are some of the many benefits of naltrexone in the treatment of drug and alcohol dependence: • Most patients experience dramatic reductions in craving within hours of taking the first dose. • Naltrexone blocks the high of alcohol and narcotics, reducing the incentive to drink or use drugs and significantly increasing treatment success. • Naltrexone is a non-habit forming medication that can be discontinued at

 

Potential Brain Cancer Therapy Seen in Affordable Diabetes Drug

Filed under: drug treatment news 2012

By Anna Azvolinsky, PhD1 | November 26, 2012. 1Freelance Science Writer and CancerNetwork Contributor. Follow Her on Twitter. Researchers have identified metformin, a drug used to treat diabetes, as a way to activate a key protein that can shut down …
Read more on Cancer Network

 

Biogen Hemophilia A Therapy Helps in Fewer Injections

Filed under: drug treatment news 2012

Biogen Idec Inc. (BIIB) and partner Swedish Orphan Biovitrum AB (SOBI) said their hemophilia A therapy controlled bleeding with fewer injections in a late-stage study. The companies plan to apply for U.S. approval early next year. The therapy, long …
Read more on Businessweek